



## CONTACT INFORMATION:

**Brian B. Berger, MD**  
[bberger@e-retina.net](mailto:bberger@e-retina.net)

**Ginger Manhart**  
[gmanhart@e-retina.net](mailto:gmanhart@e-retina.net)  
512-279-1250

- **Allergan REACH**
- **Pfizer NAION**

**Kristen Davis**  
[kdavis@e-retina.net](mailto:kdavis@e-retina.net)  
512-279-2151

- **DRCR network trials**
- **Lux Biosciences**  
**LX211-01**

**Ivana Gunderson**  
[igunderson@e-retina.net](mailto:igunderson@e-retina.net)  
512-279-1252

- **Pfizer B1181002**
- **GSK BAM114341**
- **GSK Pazopanib**



## Dr. Berger's ARVO Presence Grows

The Association for Research in Vision and Ophthalmology (ARVO) will hold its annual meeting May 6-10, 2012 in Fort Lauderdale, FL. Dr. Berger is the author of three papers this year.


- "Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy as Measured by Heidelberg Spectralis Optical Coherence," presented by Brian Berger, MD for the DRCR Network
- "A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration;" Brian Berger, MD; Joel Pearlman, MD; Jason Slakter, MD; Michael Tolentino, MD and GSK staff
- "Multicenter Phase 1 Clinical Trial Targeting Tissue Factor for the Treatment of Neovascular AMD;" Brian Berger, MD; Victor Gonzales, MD; Jack Wells, MD; Christine Gonzales, MD; Brian Sippy, MD and Iconic Therapeutics staff

## Retina Research Center wins DRCR site award

The Retina Research Center received an award of excellence for demonstrating outstanding performance in the Diabetic Retinopathy Clinical Research (DRCR) Network. DRCR is a collaborative network funded by the National Eye Institute. The network currently includes 109 participating sites and 320 physicians throughout the United States.

## 4th Year Medical Student

University of Texas Medical Branch 4th year medical student Ryan Harris is spending the month of February with Dr. Berger for his ophthalmology selective. Dr. Harris has been accepted to the University of Minnesota ophthalmology residency program.



## Dr. David Williams makes first trip to Austin

David Williams, MD, former president of The American Society of Retina Physicians, and his wife Karen joined the Bergers for a weekend in Austin. Dr. Williams is the managing partner of VitreoRetinal Surgery, PA in Minneapolis.

Retina Research Center is the **ONLY** research center in **central Texas** offering clinical trials for your patients diagnosed with **Dry Age-Related Macular Degeneration, Vitreomacular Traction, and Uveitis**. We are also participating in trials that offer patients alternative therapies to the current standard of care treatments for **Wet Age-Related Macular Degeneration**, including topical therapy. Retina Research Center is the only Texas site for treatment naïve wet AMD patients to receive the MP0-112 DARPin in the Allergan REACH clinical trial. This study is showing amazing results superior to current standard of care in some patients.

### **Enrolling Trials:**

#### **Wet Age-Related Macular Degeneration**

**GSK MD7114987**—An open-label, Phase IIA study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular age-related macular degeneration.

**Allergan REACH**—Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration.

#### **Dry Age-Related Macular Degeneration**

**GSK BAM114341**—A phase II study of GSK933776, a monoclonal antibody, in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration.

**Pfizer B1181002**—A Phase I study evaluating multiple, ascending intravenous (IV) dosages of RN6G (monoclonal antibody binding amyloid beta). The Retina Research Center has enrolled 50% of the patient population worldwide.

#### **Uveitis**

**Lux Biosciences LX211-11**—A Phase III trial evaluating LX211 (Luveniq) in patients with active noninfectious uveitis of the intermediate or posterior segments of the eye.


#### **Vitreomacular Traction**

**Thrombogenics TG-MV-014**—A Phase III study of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular traction, including Stage I and II macular holes. The Retina Research Center is in the top quarter of sites recruiting for this trial. As of February 15, 2012, this trial is 50% enrolled.

## **Brian Berger, MD now offers Spectralis with Multi-Modality Imaging**



**Sclera and Angle Structure**



**Chamber Angle**

At both our central Austin and Round Rock locations, Dr. Brian Berger now offers the Spectralis with multi-modality imaging that captures simultaneous OCT and infrared scans, providing a detailed 3-D view of the anterior chamber. The Spectralis anterior segment module consists of an add-on lens and software update that allows this new dimension in anterior chamber imaging.